trial

Dopamine and Insulin in Psychosis

NCTId NCT07252752
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Not Yet Recruiting
Enrollment 46 (estimated)
Sponsored by Medical University of Vienna
Primary completion 2029-01-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Not Yet Recruiting
Enrollment
46 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2026-01-01
Primary completion
2029-01-01
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
Intranasal InsulinLow dose insulin infusion[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)

Sponsors

Medical University of ViennaLead Sponsor

Sites

1 total
Vienna, Austria

Facts & assertions

4 sourced
Enrollment
46
Phase
NA
Primary Completion Date
2029-01-01
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Intranasal Insulin
drug
Low dose insulin infusion
drug
[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)
drug
lead_sponsor
Medical University of Vienna
company
indication
Schizophrenia
indication
First Episode Psychosis (FEP)
indication